Диссертация (1174348), страница 21
Текст из файла (страница 21)
31-36.140. Madazli, R. Comparison of clinical and perinatal outcomes in early and late-onsetpreeclampsia / Madazli R. // Arch Gynecol Obstet. – 2014. – Vol. 290(1). P. 53-57.141. Magee, L.A. Expectant management of severe preeclampsia remote from term: astructured systematic review / Magee L.A., Yong P.J., Espinosa V., Cote A.M.,Chen I., von Dadelszen P. // Hypertension in pregnancy.
– 2009. – Vol. 28(3). – P.312- 47.142.Masoura, S. Biomarkers of endothelial dysfunction in preeclampsia andneonatal morbidity: a case-control study / S. Masoura [et al.] // Eur J ObstetGynecol Reprod Biol. – 2014. – Vol. 175. – Р. 119-123.143. Masuyama, H. Different profiles of circulating angiogenic factors andadipocytokines between early- and late-onset pre-eclampsia / H. Masuyama [et al.]// BJOG. – 2010. – Vol. 117, № 3. – Р. 314-320.144. Matsubara, K.
Role of nitric oxide and reactive oxygen species in the130pathogenesis of pre-eclampsia / K. Matsubara [et al.] // J Obstet Gynaecol Res. –2010. – Vol. 36, № 2. – Р. 239-247.145. Maynard, S.E. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) maycontribute / Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al.// J Turk Ger Gynecol Assoc. – 2014. – Vol.15. – P. 30-5.146.
McKeeman, G.C. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) isincreased throughout gestation in patients who have preeclampsia develop /McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., McClure N. // Am JObstet Gynecol. – 2004. – Vol. 191. – P. 1240-6.147. McKinney, A.M. Posterior reversible encephalopathy syndrome: incidence ofatypical regions of involvement and imaging findings / McKinney A.M. [et al.] //Am J Roentgenol. – 2007. – Vol.189. – P. 904–912.148. Medica, I. Genetic polymorphisms in vasoactive genes and preeclampsia: a metaanalysis / I. Medica, A.
Kastrin, B. Peterlin // Eur J Obstet Gynecol Re- prod Biol.– 2007. – Vol. 131, № 2. – Р. 115-126.149. Mellembakken, J.R. Activation of leukocytes during the uteroplacental passage inpreeclampsia / Mellembakken J.R., Aukrust P., Olafsen M.K., Ueland T., HestdalK., Videm V. // Hypertension. – 2002. – Vol. 39(1).
– P. 155–60.150.Mirahmadian, M. Association of tumor necrosis factor-alpha and interleukin-10gene polymor- phisms in Iranian patients with pre-eclampsia / M. Mirahmadian [etal.] // Am. J. Reprod. Immunol. – 2008. – Vol. 60, № 2. – Р. 179-185.151. Mitani M. Clinical features of fetal growth restriction complicated later bypreeclampsia / Mitani M. et al // J. Obstet. Gynaecol. Res.
– 2009. – Vol. 35 (5). –P. 882-887.152. Mohajertehran, F. Association of single nucleotide polymorphisms in the humantumor necrosis factor-α and interleukin 1-β genes in patients with pre-eclampsia /F. Mohajertehran [et al.] // Iran J Allergy Asthma Immunol. – 2012. – Vol. 11, №3. – Р. 224-229.153. Molvarec, A. Association between tumor necrosis factor (TNF)-alpha G-308Agene polymorphism and preeclampsia complicated by severe fetal growth131restriction / A. Molvarec [et al.] // Clin Chim Acta.
– 2008. – Vol. 392, № 1-2. – Р.52-57.154. Moore Simas, T.A. Angiogenic biomarkers for prediction of early preeclampsiaonset in high-risk women / T.A. Moore Simas [et al.] // J Matern Fetal NeonatalMed. – 2014. – Vol. 27, № 10. – Р. 1038-1048.155. Morbidelli, L. Nitric oxide mediates mitogenic effect of VEGF on coronaryvenular endothelium / Morbidelli L., Chang C.H., Douglas J.G., Granger H.J.,Ledda F., Ziche M.
// Am J Physiol. – 1996. – Vol. 270. – P. 411-5.156. Muto, H. Risk assessment of hypertensive disorders in pregnancy with maternalcharacteristics in early gestation: A single-center cohort study / H. Muto [et al.] //Taiwan J Obstet Gynecol. – 2016. – Vol.55, №3. – Р.341-345.157. Nikuei, P. The imbalance in expression of angiogenic and anti-angiogenic factorsas candidate predictive biomarker in preeclampsia / Nikuei P., Malekzadeh K.,Rajaei M., Nejatizadeh A., Ghasemi N. // Iran J Reprod Med.
– 2015. – Vol. 13(5).- P. 251-62.158. Nishizawa, H. Analysis of nitric oxide metabolism as a placental or maternalfactor underlying the etiology of pre-eclampsia / H. Nishizawa [et al.] // GynecolObstet Invest – 2009. – Vol. 68, № 4. – Р. 239-247.159. Odendaal, H.J. Aggressive or expectant management for patients with severepreeclampsia between 28-34 weeks gestation: a randomized controlled trial /Odendaal H.J., Pattinson R.C., Bam R.
et. all. // Obstetrics and Gynecology. –1990. – Vol. 76. – P. 1070-5.160. Oudejans, C.B. Genetics of preeclampsia: paradigm shifts / Oudejans C.B., vanDijk M., Oosterkamp M., Lachmeijer A., Blankenstein M.A. // Hum Genet. –2007. – Vol. 120. – P. 607-612.161. Ozturk, E. Endothelial nitric oxide synthase gene polymorphisms in preeclampsiawith or without eclampsia in a Turkish population / E. Ozturk [et al.] // J ObstetGynaecol Res. – 2011. - Vol. 37, № 12. – Р. 1778-1783.162. Palei, A.C.
Pathophysiology of hypertension in pre-eclampsia: a lesson inintegrative physiology / Palei A.C., Spradley F.T., Warrington J.P., George E.M.,132Granger J.P. // Acta Physiol (Oxf). – 2013. – Vol. 208. – P. 224–33.163. Pang, Z.J. Comparative study on the expression of cytokine – receptor genes innormal and preeclamptic human placentas using DNA microarrays / Pang Z.J.,Xing FQ. // J Perinat Med. - 2003. – Vol. 31(2). – P. 153–6210.164.
Park, H. J. Combined screening for early detection of pre-eclampsia / H. J. Park,S. S. Shim, D. H. Cha // Int. J. Mol. Sci. – 2015. – Vol. 16. – Р. 17952-17974.165. Pavlakis, S.G. Occipital-parietal encephalopathy: a new name for an oldsyndrome. Pavlakis S.G. [et al.] // Pediatr Neurol. – 1997. – Vol.16(2). – P.145–148.166. Pazarbaşi, A.
Polymorphisms in the tumor necrosis factor-alpha gene in Turkishwomen with pre-eclampsia and eclampsia / A. Pazarbaşi [et al.] // Acta MedOkayama. – 2007. – Vol. 61, № 3. – Р. 153-160.167. Pereira, R.D. Angiogenesis in the Placenta: The role of Reactive Oxygen SpeciesSignaling / Pereira R.D. [et al.] // Biomed Res Int. – 2015. – doi:10.1155/2015/814543.168. Phipps, E. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines /Phipps E. [et al.] // Clin J Am Soc Nephrol. – 2016. – Vol.6.
– №11(6). – P.11021113.169. Pinheiro, M.B. Severe preeclampsia: association of genes polymorphisms andmaternal cytokines production in Brazilian population / M. B. Pinheiro [et al.] //Cytokine. – 2015. – Vol. 71, № 2. – Р. 232-237.170. Powers, R.W. Evidence of endothelial dysfunction in preeclampsia and risk ofadverse pregnancy outcome / R.W. Powers [et al.] // Reprod. Sci. – 2008.
– Vol.15, № 4. – Р. 374–381.171. Prochazka, M. Markers of endothelial activation in preeclampsia / M. Prochazka[et al.] // Clin Lab. – 2015. – Vol. 61, № 1-2. – Р. 39-46.172. Ramsay, J.E. Enhancement of endothelial function by pregnancy / J.E. Ramsay[et al.] // Diabetes Care. – 2003. – Vol. 26. – Р. 475–479.173. Raymond, D. A critical review of early-onset and late-onset preeclampsia /Raymond D., Peterson E. // J. Obstet Gynecol Surv. – 2011. – Vol. 66. – P. 497–133506.174.
Reddy, A. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglinat parturition in normal pregnancy and pre-eclampsia / Reddy A., Suri S., SargentI.L., Redman C.W., Muttukrishna S. // PLoS One. – 2009. – Vol. 4. – P. 44-53.175. Redman, C.W. Placental stress and pre-eclampsia: a revised view / Redman C.W,Sargent I.L. // Placenta. – 2009. – Vol. 30.
– P. 38–42.176. Reis, Z.S. Early-onset preeclampsia: is it a better classification for maternal andperinatals? / Z. S. Reis [et al.] // Rev Bras Ginecol Obstet. – 2010. – Vol. 32, №12. – Р. 584-590.177. Reister, F. The distribution of macrophages in spiral arteries of the placental bedin pre-eclampsia differs from that in healthy patients / Reister F., Frank H.G., HeylW., Kosanke G., Huppertz B., Schröder W., et al. // Placenta. – 1999. – Vol. 20(2–3).
– P. 229–3310.178. Reslan, O.M. Molecular and vascular targets in the pathogenesis and managementof the hypertension associated with preeclampsia / Reslan O.M., Khalil R.A. //Cardiovasc Hematol Agents Med Chem. – 2010. – Vol. 8. – P.
204–26.179. Romao, M. TLR-4 expression and pro-inflammatory cytokine production byperipheral blood monocytes from preeclamptic women / M. Romao [et al.] //Pregnancy Hypertens. – 2012. – Vol. 2, № 3. – Р. 276-283.180. Sakar, M.N. Association of endothelial nitric oxide synthase gene G894Tpolymorphism and serum nitricoxide levels in patients with preeclampsia andgestational hypertension / M.N. Sakar [et al.] // J Matern Fetal Neonatal Med. –2015. – Vol. 28, № 16. – Р.
1907-1911.181. Savvidou, M.D. Endothelial nitric oxide synthase gene polymorphism andmaternal vascular adaptation to pregnancy / M.D. Savvidou [et al.] //Hypertension. – 2001. – Vol. 38. – P. 1289-1293.182. Schiff, E. Conservative management of severe preeclampsia remote from term /Schiff E., Friedman S.A., Sibai B.M.
// Obstet Gynecol. – 1994. Vol. 84. – P. 626–630.183. Schoen, J.C. Headache in pregnancy: An Approach to Emergency Department134Evaluation and Managment / Schoen J.C., Cmpbell R.L., Sadosty A.T. // WesternJournal of Emergency Medicine. – 2015. – Vol.2. – P.291-299.184. Schonkeren, D. Differential distribution and phenotype of decidual macrophagesin preeclamptic versus control pregnancies / Schonkeren D., van der Hoorn M.L.,Khedoe P., Swings G., van Beelen E., Claas F., et al. // Am J Pathol. – 2011.
– Vol.178(2). – P. 709–1710.185. Serrano, N.C. Endothelial NO synthase genotype and risk of preeclampsia amulticenter case-control study / N.C. Serrano [et al.] // Hypertension. – 2004. –Vol. 44. – Р. 702- 707.186. Sharma, A. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8)in pre- eclamptic, normotensive pregnant and healthy non-pregnant women / A.Sharma [et al.] // Am.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
